Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.19
Views: 341

Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China

Dr Yu Hu presents data from a study looking at bispecific CAR-T Cell therapy in patients with multiple myeloma during a press conference at ASH 2019.

The study evaluated the sustainability of remissions in this hard to treat multiple myeloma.

Read more about the study here

Watch our interview with Dr Yu Hu here

Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation